Prolacta Bioscience

Prolacta Bioscience, Inc. (www.prolacta.com) is a life science company founded by serial entrepreneur, Elena Medo who has dedicated her career to improving quality of life for sick infants by Advancing the Science of Human MilkTM. Prolacta creates specialty formulations made exclusively from human milk for the nutritional needs of critically ill, premature infants in neonatal intensive care units. It is the first and only company to provide a human milk fortifier made from 100% human milk, Prolact+ H2MF. They operate a pharmaceutical grade processing plant and have designed and patented processes that enable them to make their one-of-a-kind life saving products. Prolacta is committed to making a meaningful difference in the lives of the most vulnerable infants through world-class research and innovative products.

Prolacta Bioscience headquartered in United States, North America, operates in the Biotechnology, Life Science, Health Care, Nutrition sector. The company focuses on Biotechnology and has secured $10.0B in funding across 128 round(s). With a team of 251-500 employees, Prolacta Bioscience is actively contributing to advancements in Biotechnology. Their latest funding round, Series D - Prolacta Bioscience, raised $15.0M. Discover more about their projects, partnerships, and impact on our platform.